Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial  by MacLeod, Nicholas et al.
944 Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015
Introduction: Radiotherapy is often used to treat pain in malignant 
pleural mesothelioma (MPM), although there is limited evidence to 
support this. The aim of this trial was to assess the role of radio-
therapy for the treatment of pain in MPM.
Methods: A multicentre, single arm phase II trial was conducted. 
Eligible patients fulfilled the following criteria: pathological or radio-
logical diagnosis of MPM; pain secondary to MPM; radiotherapy 
indicated for pain control; and more than 18 years of age. Patients 
had assessments of pain and other symptoms at baseline and then 
received 20 Gy in five daily fractions. Key follow-up points were 
5 and 12 weeks posttreatment. The primary end point measure was 
assessment of pain at the site of radiotherapy at 5 weeks. Secondary 
end points included effects on quality of life, breathlessness, fatigue, 
mood, toxicity, and the radiological response.
Results: Forty patients were recruited from three UK oncology centers. 
Fourteen patients had a clinically meaningful improvement in their pain 
5 weeks post radiotherapy (intention to treat), with five patients having a 
complete improvement. On the basis of a complete case analysis of the 
30 patients assessable at week 5, 47% (confidence intervals, 28.3–65.7) 
of patients alive at week 5 had an improvement in their pain. There was 
no improvement in other key symptoms or quality of life.
Conclusions: Radiotherapy for pain control in MPM is an effective 
treatment in a proportion of patients. Future studies examining dif-
fering radiotherapy regimens with a view to improving response rates 
are warranted.
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Malignant pleural mesothelioma (MPM) is a malignancy affecting the pleural lining. Exposure to asbestos is the 
most common etiological factor, and although it is a relatively 
rare malignancy, the incidence of MPM in the United Kingdom 
is among the highest in the world and is set to rise further in the 
next few years.1,2 Its rarity is in contrast to its clinical effect. The 
median survival is 12 months, and lack of effective treatments 
means that it represents one of the main therapeutic challenges 
in Oncology.3–5 As a result, the vast majority of patients are 
symptomatic of the disease and die from the condition.
MPM carries a high symptom burden, and pain is the 
most common. Various analgesics, including strong opioids, 
nonsteroidal anti-inflammatory drugs, anticonvulsants, local 
anesthetic agents, and steroids, are used. Despite these, pain 
control is often suboptimal.6
Over the last three decades, radiotherapy has been used 
as a key analgesic modality in MPM. Although this is widely 
accepted as a therapeutic option, a recent systematic review 
reported that there is limited evidence to support the role of 
radiotherapy in treating pain in MPM.7 Studies to date have 
used a wide variety of doses and fractionation regimens, 
which have resulted in no clear consensus on the optimal 
radiotherapy regimen. Moreover, there have been no prospec-
tive studies using validated end points, although a previous 
study from Glasgow suggested some short-term benefit.8 As a 
result, little can be drawn from these data in terms of inform-
ing practice. On the basis of the current evidence, which is 
mainly retrospective, the response rates using radiotherapy to 
treat pain in MPM vary from 0% to 69%. There is a need for 
prospective studies using standard radiotherapy regimens and 
validated end points, which examine radiotherapy for treating 
pain in MPM. Therefore, the SYSTEMS study was conducted 
to assess the role of radiotherapy for pain control in MPM 
using standard radiotherapy regimens, controlled background 
analgesia, and validated assessment tools.
MATERIALS AND METHODS
A multicenter, single arm, phase II study was conducted. 
The study had independent ethics committee approval (UK–12/
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WS/0134) and was conducted in accordance with the Declaration 
of Helsinki. It was registered at the ISRCTN database (66947249). 
There was one major protocol modiﬁcation, which was an amend-
ment to include positron emission tomography–computed tomog-
raphy (PET-CT) scanning to assess a possible role in radiotherapy 
planning in MPM. These ﬁndings will be presented elsewhere. 
This was discussed and approved by the Trial Steering Committee 
and occurred after 19 patients had been consented.
Patients
Eligible patients fulﬁlled the following criteria: 18 years of 
age or over; histological or agreed clinical and radiological diag-
nosis of MPM by thoracic oncology multidisciplinary team; due 
to receive radiotherapy (indication pain resulting from MPM); 
Eastern Cooperative Oncology Group performance status 0–2; 
CT scan within the previous 8 weeks; and had pain ≥4 of 10 (worst 
pain in the previous 24 hours) on a 0–10 visual analogue scale.
Patients who had received radiotherapy or chemother-
apy in the preceding 6 weeks that was likely to alter pain dur-
ing the duration of the trial or planned chemotherapy during 
the trial period were excluded.
The trial was conducted in three regional cancer cen-
ters in the United Kingdom (Beatson West of Scotland Cancer 
Centre, Edinburgh Cancer Centre, and Weston Park Hospital 
NHS Trust, Shefﬁeld).
Trial Design
Before consent, all patients were assessed and had their 
current analgesia optimized. The aim of this was to stabilize 
analgesia before radiotherapy, with the purpose of minimiz-
ing the likelihood of changes in analgesia during the trial. 
This was undertaken to enable, where possible, the true effect 
of radiotherapy to be seen. Consenting patients would have 
stable but poorly controlled pain, necessitating the need for 
radiotherapy.
After obtaining written informed consent, all baseline 
assessments were performed. Patients then underwent radio-
therapy planning and subsequently started treatment a maxi-
mum of 7 days from trial baseline.
Radiotherapy
Wire markings were placed on the skin to outline the 
outer limits of the painful area. Radiotherapy was planned 
using CT simulation either by CT ﬁeld placement or by volum-
ing of the tumor using an Eclipse workstation. All planning CTs 
were captured on LightSpeed Simulator LS RT 16 GE Medical 
CT scanner (GE Medical systems, Crawley, United Kingdom) 
using a 120 kV automatic mA modulation range of 15–240 
mAs with 50 cm Dual Field of View. When the target area was 
contoured, the gross tumor volume was deﬁned as the volume 
of tumor, which was felt to be responsible for the pain. This was 
then grown to a planning target volume (PTV) by 1–2 cm, sub-
ject to the discretion of the treating clinician. All patients were 
planned to receive 20 Gy in ﬁve fractions to the area of pain.
During the trial, assessments were performed at weeks 
1, 5, and 12 after the start of radiotherapy. Patients were also 
contacted by telephone every week to monitor for any adverse 
events and assess analgesia.
End Points
The primary end point was level of pain 5 weeks after 
radiotherapy. An improvement in pain was deﬁned as a ≥30% 
reduction in pain from baseline. Pain was assessed using the 
brief pain inventory (BPI), which has been extensively vali-
dated in cancer pain. An improvement of ≥30% is accepted 
as a clinically meaningful improvement in pain in studies of 
analgesic interventions.9 Opioid analgesic use was recorded 
and is reported in morphine equivalent daily dose (MEDD) to 
allow comparison between different opioid types and to enable 
the effect of changes in analgesia with respect to changes in 
pain after radiotherapy.
Secondary end points assessed the effect of radiotherapy 
at weeks 1, 5, and 12 on the following: pain response at weeks 
1 and 12; dyspnea assessed using a numerical rating scale; 
mood assessed using the Hospital Anxiety and Depression 
Scale; quality of life (QoL) using the EORTC QLQ-30; 
fatigue using the Fatigue Severity Scale (FSS); night sweats 
assessed using an numerical rating scale; radiotherapy toxic-
ity as per common toxicity criteria for adverse events version 
4.0; and the effect of radiotherapy on tumor bulk assessed by 
comparing CT scans at week 12 with baseline CT using the 
modiﬁed response evaluation criteria in solid tumors.10
Statistical Considerations
The statistical analysis was based on the objective of 
showing the proportion of patients for whom radiotherapy 
was an effective means of treating pain in MPM at 5 weeks 
post radiotherapy. A sample size of 40 patients was calcu-
lated to enable the proportion of responders to be estimated 
within ≤15%, depending on the true underlying proportion. 
An intention to treat (ITT) approach was used. The secondary 
end points were exploratory in nature.
All statistical analyses were performed using SPSS 
version 21.0 (Chicago, IL). Unless otherwise stated, means 
and standard deviations (SD) are used, and 95% conﬁdence 
intervals (CI) are reported throughout. Patients who met the 
primary end point are termed “responders” and patients who 
did not are termed “nonresponders.”
RESULTS
Patient disposition is shown in the CONSORT diagram 
in Figure 1. From June 2012 to December 2013, 40 patients 
consented to the trial. Of these, 37 patients started radiother-
apy, with 35 completing their prescribed course. All sites of 
pain were in the chest.
Patient demographics are shown in Table 1. Thirty-ﬁve 
patients were male, and the median age (interquartile range 
[IQR]) was 71.50 (65.00–76.00) years. The most common 
histological type was epithelioid in 21 patients (56.8%), 
and the majority of patients were performance status 1 or 2. 
The median survival from the time of trial registration was 
93 days (CI, 68–118). However, this differed depending on 
histological subtypes—epithelioid 124 days (83–165) versus 
sarcomatoid 65 (37–93), p = 0.04. The mean (SD) time from 
initial diagnosis to study entry was 249.41 days (274.16). The 
median (IQR) baseline BPI score was 57 (42.0–65.5), and the 
median (IQR) baseline opioid dose was 55 mg (25–210).
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At the time of primary end point assessment (week 5), 
30 patients were evaluable. Three patients did not start radio-
therapy, two patients failed to complete radiotherapy, two 
patients had died before week 5, and three further patients 
had deteriorated to the point that they were no longer able 
to complete the assessment (Fig. 1). The primary end point, 
based on an ITT analysis, was met by 14 patients (35%) who 
had a clinically signiﬁcant improvement in pain 5 weeks post 
radiotherapy. Nine patients (22.5%) had an improvement of 
≥60% in BPI score with ﬁve patients (12.5%) having a com-
plete response (100% improvement in BPI). Therefore, based 
on a complete case analysis of 30 evaluable patients at week 
5, 47% (CI, 28.3–65.7) of patients responded to the radiother-
apy. Of the 14 patients who responded to radiotherapy, eight 
had epithelioid histology, four had sarcomatoid, and two had 
mixed histology. As a percentage of the total number of each 
of these histological subtypes, 38% of epithelioid patients 
responded, 40% of sarcomatoid, and 66.6% of mixed histol-
ogy. There was no statistically signiﬁcant difference between 
histological subtypes in terms of response.
At weeks 1 and 12, the pain response rate was 27.5% 
(CI, 14–6% to 43.9%) and 15.0% (CI, 5.7–29.8%), respec-
tively, on an ITT analysis. On the basis of a complete case 
analysis, the proportion of pain responders at week 1 was 
36.7% (CI, 19.9–56.1%) and at week 12 was 33.3% (CI, 
13.3–59.0%). Although 32 patients completed the week 1 
assessment, two of them had incomplete data and so were not 
evaluable. Eighteen patients were evaluable at week 12.
Figure 2 shows changes in opioid dose and pain (BPI) 
per responder status. Only four responders had an increase in 
their opioid dose between study baseline and end point, and in 
only one patient was this >20 mg (MEDD). There was no dif-
ference in mean opioid dose between baseline and end point in 
the responders, p = 0.627. There was no difference in the per-
centage change from baseline MEDD at week 1 (p = 0.577) or 
week 5 (p = 0.355) between responders and nonresponders. Of 
the 14 responders, nine were on simple and eight on adjuvant 
analgesics at baseline. A similar proportion (16 of 24) of the 
nonresponders was on simple analgesics at baseline. Although 
a slightly higher proportion (17 of 24) of nonresponders was 
on adjuvant analgesics at baseline compared with responders, 
this was not statistically signiﬁcant, p = 0.391. Throughout the 
duration of the study, only one patient was started on an adju-
vant analgesic. Therefore, the improvement in pain is likely 
due to radiotherapy rather than analgesia.
There was no change in global QoL for patients 
throughout the study when they are taken as a whole group. 
However, there was a trend suggesting an improvement in 
QoL in responders and a decline in global QoL in nonre-
sponders, although this was not statistically signiﬁcant. The 
FIGURE 1. Patient disposition.
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median improvement in QoL in responders was 12.50 (IQR, 
−16.67 to 41.67) compared with a median decline of 12.50 
(IQR, −25.00 to 0.00) in nonresponders. In terms of speciﬁc 
QoL components, there was a worsening of fatigue, appetite 
loss, and nausea/vomiting scores. Fatigue scores at week 12 
(p = 0.040) and nausea/vomiting at week 1 (p = 0.017) had 
signiﬁcantly increased. There were, however, improvements 
in pain, dyspnea, insomnia, and constipation. Pain scores at 
weeks 1 (p = 0.005) and 5 (p = 0.034) and dyspnea at week 
1 (p = 0.037) were signiﬁcantly lower. There was no signiﬁ-
cant difference between responders and nonresponders in 
the change in dyspnea score at week 5 (responders: median 
change, 0; IQR, −33 to 33; nonresponders: −16.67, IQR −33 
to 0; p = 0.203). The greater improvement in nonresponders 
may be due to baseline dyspnea score being higher than for 
responders, although not signiﬁcantly so (p = 0.148). Only 
one patient had a cough, which was recorded as grade 2 at all 
times including baseline.
The effect of radiotherapy on other key symptoms is 
shown in Table 2. There was no signiﬁcant change in any 
other secondary end points with the exception of night sweats, 
which improved by week 5 (p = 0.01).
In Table 3, the percentage of patients with the most 
common symptoms and likely side effects from radiotherapy 
are reported. Only one patient had a delay in delivery of their 
radiotherapy because of radiotherapy induced odynophagia, 
however, this patient had an apical tumor, and their larynx 
was within the radiotherapy ﬁeld. The patient had been given 
additional analgesia as prophylactic cover but had not taken 
it. On commencing the analgesia, the patient’s odynophagia 
improved considerably, and he completed the radiotherapy.
Changes in disease bulk, assessed using CT, are shown 
in Table 4. Only 18 patients were alive and well enough to 
undergo the week 12 CT. Of these, there was only one par-
tial response as assessed by the modiﬁed response evaluation 
criteria in solid tumors criteria for assessment of response in 
MPM.10 None of the ﬁve patients who had radiological pro-
gressive disease had a drop in their BPI score.
The median PTV was 1046.70 cm3 (IQR, 731.50–
1339.90). There was no difference between the median PTV 
for responders—1004.00 cm3 (IQR 585.20–1312.00)—and 
non responders—1104.85 cm3 (IQR, 795.00–1356.85) sug-
gesting that the size of the PTV does not correlate with the 
magnitude of response.
Median survival of responders was 106 days (95% CI, 
86–126 days). Median survival was slightly lower in nonre-
sponders at 93 days (95% CI, 18–168 days), but the difference 
was not statistically signiﬁcant (p = 0.465).
DISCUSSION
This is the largest trial to date that examines the role 
of radiotherapy in MPM and the ﬁrst to use validated assess-
ment tools in this setting. The ﬁndings support that radio-
therapy is an effective treatment for a proportion of patients 
with MPM-related pain with 35% of assessable patients 
experiencing a clinically meaningful improvement in their 
pain. Of these, 12.5% had a complete improvement in their 
pain. There was no association between pain response and 
TABLE 1. Patient Demographics
Characteristic n % Mean SD Median IQR
Age 71.50 65.00–76.00
Male 35 87.5
ECOG
  0 3 7.5
  1 18 45.0
  2 19 47.5
Time from diagnosis to trial entry 
(days)
249.41 274.16
Mesothelioma
  Histology
   Epithelioid 21 56.8
   Sarcomatoid 10 27
   Mixed 3 8.1
   Other 3 8.1
   Not available 3 8.1
  Metastases
   Present 12 30.0
   Absent 27 71.1
   Unknown 1 2.5
Previous anticancer therapy for MPM
  Chemotherapy 14 36.8
  Radiotherapy 1 2.5
SD, standard deviation; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group.
948 Copyright © 2015 by the International Association for the Study of Lung Cancer
MacLeod et al. Journal of Thoracic Oncology ® • Volume 10, Number 6, June 2015
improvement in any other symptoms, and therefore, pal-
liative radiotherapy in MPM should only be considered for 
pain control.
There has been a lack of previous work in this area, with 
which to compare our ﬁndings. The only other prospective 
study that has examined radiotherapy in MPM reported 22 
patients who were treated with hemithoracic irradiation using 
Cobalt-60 machines at a dose of 30 Gy in 10 fractions. Pain 
scores improved in 13 patients 1 month after radiotherapy 
with no increase in analgesic requirements. Validated pain 
assessment tools were not used in this study, though none were 
available at the time.8
The ﬁndings of the present study are, therefore, of inter-
est and provide evidence to support radiotherapy as a useful 
modality for treating pain in MPM. Of particular note was 
that in 12.5% of patients a complete analgesic response was 
noted. This provides grounds for optimism for future work 
in this area. Future work should examine dose escalation, 
both in terms of total dose and dose per fraction, because 
the likelihood of improving outcomes by increasing dose 
FIGURE 2. A, Waterfall plot of percentage change from baseline to week 5 in total BPI score and (B) corresponding raw 
change from baseline to week 5 in morphine equivalent daily dose. The dotted line indicates a 30% reduction from baseline BPI 
score, the “response” criterion. Note, a further 10 patients were classed as nonresponders, but have missing baseline and/or 
week 5 BPI total score.
TABLE 2. Symptom Assessments Between Trial Baseline and Other Timepoints
Symptom (score) Baseline mean (SD) Week 1 mean (SD) P Value Week 5 mean (SD) P Value Week 12 mean (SD) P Value
Dyspnea (0–10) 4.46 (2.47) 4.19 (2.84) 0.44 5.26 (2.35) 0.09 4.95 (3.08) 0.263
Sweats (0–10) 3.44 (3.58) 3.16 (3.29) 0.22 2.00 (3.02) 0.01 1.79 (2.74) 0.425
HADS anxiety (0–21) 5.86 (4.17) 4.90 (4.15) 0.23 5.66 (4.58) 0.85 6.41 (4.93) 0.524
HADS depression (0–21) 6.86 (3.41) 6.97 (4.09) 0.83 7.41 (4.15) 0.30 7.65 (3.55) 0.176
Fatigue (0–63) 49.08 (11.88) 45.30 (13.71) 0.13 48.21 (11.29) >0.99 49.00 (13.76) 0.514
HADS, hospital anxiety and depression scale.
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per fraction varies between tumor types and is determined 
by the α/β ratio of the tumor. Although rapidly proliferating 
squamous cell carcinomas, such as head and neck or cervi-
cal cancer, have high α/β ratios and beneﬁt from treatment 
with small doses per fraction, many nonsquamous tumors 
with lower proliferation rates have low α/β ratios and hence 
beneﬁt from higher doses per fraction.11,12 Although there are 
little data from which to estimate the α/β ratio for MPM, 
its nonsquamous histology, relatively low proliferation 
index, mesenchymal origin, and apparent radioresistance are 
all consistent with a low α/β value. This hypofractionated 
approach would also have the advantage of reducing hospital 
visits and delivering palliative treatment in a timely fashion, 
which are clearly important in patients with limited survival, 
as is the limited toxicity seen here. Therefore, dose escala-
tion studies, ideally delivered using advanced radiotherapy 
techniques, such as intensity modulated radiotherapy, to help 
provide adequate coverage of bulky areas of disease, while 
sparing critical normal tissues including lung and would 
seem the obvious next step.
There are certain characteristics of the study population 
that should be highlighted. Only 35% patients had received 
prior chemotherapy, which is lower than that would be antic-
ipated for patients with MPM. However, the median age of 
patients in the study was 71 years compared with 60 years 
in previous studies examining the use of chemotherapy in 
MPM.4,5 Furthermore, an epidemiological study showed that, 
over a 4-year period, only 54 of 146 patients were considered 
TABLE 3. Common Toxicity Criteria for Adverse Event Grades at Each Trial Timepoint
Baseline Week 1 Week 5 Week 12
n % n % n % n %
Anorexia Grade 0/1 31 83.8 31 83.8 30 90.9 17 85.0
Grade 2 4 10.8 4 10.8 3 9.1 3 15.0
Grade 3 2 5.4 2 5.4 0 0.0 0 0.0
Not assessed/deceased 0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
Dyspnea Grade 0/1 17 45.9 18 48.6 14 42.4 10 50.0
Grade 2 17 45.9 17 45.9 15 45.5 6 30.0
Grade 3 3 8.1 2 5.4 4 12.1 4 20.0
Not assessed/deceased 0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
Fatigue Grade 0/1 13 35.1 15 40.5 12 36.4 9 45.0
Grade 2 14 37.8 14 37.8 10 30.3 6 30.0
Grade 3 10 27.0 8 21.6 11 33.3 5 25.0
Not assessed/ 
deceased
0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
Hyperhidrosis Grade 0/1 35 94.6 37 100.0 31 93.9 20 100.0
Grade 2 2 5.4 0 0.0 2 6.1 0 0.0
Not assessed/deceased 0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
Pain Grade 0/1 22 59.5 35 94.6 32 97.0 18 90.0
Grade 2 4 10.8 2 5.4 1 3.0 1 5.0
Grade 3 11 29.7 0 0.0 0 0.0 1 5.0
Not assessed/deceased 0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
Pleuritic pain Grade 0/1 27 73.0 22 59.5 16 48.5 9 45.0
Grade 2 7 18.9 6 16.2 10 30.3 6 30.0
Grade 3 3 8.1 9 24.3 7 21.2 5 25.0
Not assessed/deceased 0 0.0 0 0.0 4 0.0 17 0.0
Total 37 100.0 37 100.0 37 100.0 37 100.0
TABLE 4. Computed Tomography Response at 12 Weeks 
Evaluated as per Modified Recist 1.1
n %
Assessment of overall 
response in target lesions
CR 0 0.0
PR 1 2.5
SD 13 32.5
PD 5 12.5
Not evaluable 21 52.5
Total 40 100.0
CR, complete response; PR, partial response; SD, stable disease, PD, progressive 
disease.
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ﬁt for chemotherapy and of that, only 28 (18%) received che-
motherapy.13 Therefore, the ﬁgure reported in the present study 
appears to be representative of the population from which the 
study patients were recruited.
The percentage of patients in the study with epithelioid 
histology was 56.8%. This is perhaps lower than that would 
have been anticipated and is certainly lower than either of the 
two phase III chemotherapy trials that showed a survival advan-
tage for cisplatin in combination with an antifolate agent.4,5 
Sarcomatoid histology, seen in 27% of patients in this study 
compared with between 1% and 8% in those chemotherapy 
studies, is associated with a signiﬁcantly worse prognosis than 
epithelioid histology.5 This would suggest that patients receiv-
ing radiotherapy for pain control are a very different popula-
tion from those studied in previous chemotherapy trials.
Despite the improvement in pain, there was no improve-
ment in QoL or other symptoms, although there was a trend 
toward improved QoL in those who responded to radiother-
apy. There may be many explanations for this. Primarily, these 
patients are near the end of life as shown by the median sur-
vival of 3.1 months in this trial. QoL naturally deteriorates 
during this time. In addition, multiple symptoms coexist in 
MPM, such as dyspnea and fatigue, and these are unlikely to 
be influenced by an improvement in pain. Similar results have 
been found in chemotherapy studies in MPM where no QoL 
improvements have been observed.3 This may also reflect a 
generic problem associated with attempts to study QoL out-
comes in patients with advanced cancers in which patient 
attrition and general deterioration make it very difﬁcult to 
detect treatment-related changes in QoL.
The SYSTEMS trial has limitations. The most obvious 
of these is the small sample size. However, this was designed 
as a single arm observational trial, and the main aim was to 
inform future, larger scale studies; this has been achieved. 
Another limitation was the very high attrition rate within the 
trial with only 75% of patients being evaluable 5 weeks after 
radiotherapy. This highlights the poor survival of these patients 
and the fact that, by the time most patients with MPM develop 
signiﬁcant, uncontrolled chest pain, and they are usually at an 
advanced stage of their illness. Another potential limitation was 
the choice of radiotherapy regimen. This is no consensus on the 
standard radiotherapy technique for treating patients with MPM 
with palliative intent, so a rather conservative dose and regimen 
was selected because it was widely used in the study centers. 
We cannot comment on whether pain improvement persisted 
beyond 12 weeks as this timepoint was the end of the study.
CONCLUSION
Palliative radiotherapy can be an effective method for 
treating pain in MPM, and in a proportion of patients is asso-
ciated with dramatic improvements in pain. These ﬁndings 
provide a foundation for current practice and highlight that 
radiotherapy studies in complex tumors, such as MPM, are 
feasible. Dose escalation studies that aim to increase response 
rates are now eagerly awaited.
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